Joins Dr. Beckman and Wallace Coulter as Fellows of American Institute for Medical and Biological Engineering (AIMBE)
INDIANAPOLIS – (April 18, 2016) – The American Institute for Medical and Biological Engineering (AIMBE) has elected Dr. Yong Chen, the Chief Technology Officer of Beckman Coulter Life Sciences, a Danaher company, to its College of Fellows. This is in recognition of his work in the field of medical and engineering innovation and discovery.
This honor follows in the footsteps of the founding fathers of the company, Dr. Arnold Beckman and Wallace Coulter, both previous fellows of this prestigious organization.
“In honoring Dr. Chen, the AIMBE recognizes the impact the CytoFLEX flow cytometer’s outstanding technology has had on the life sciences research space,” explained Mario Koksch, Vice President and General Manager of the Flow Cytometry Business Unit, Beckman Coulter Life Sciences.
“With its use of disruptive technologies, the CytoFLEX sets new standards of fluorescence sensitivity, enabling scientists to expand into new research areas using side scatter off the violet laser for enhanced nanoparticle detection.”
In 2012, Dr. Chen founded Xitogen Technologies Inc., a China-based startup to develop a revolutionary life science instrument. Xitogen was acquired by Danaher two years later; and Dr. Chen has spearheaded the production of the first new instrument to be launched since the acquisition, the Beckman Coulter CytoFLEX Flow Cytometer.
“I am honored to be recognized by the AIMBE and to join such an illustrious group of fellows,” Dr. Chen explained. “The considerable research facilities offered by Beckman Coulter Life Sciences, not just in the field of flow cytometry, creates a stimulating and innovative environment in which to explore the frontier of medical and biological engineering.”
INDIANAPOLIS – (April 18, 2016) – The American Institute for Medical and Biological Engineering (AIMBE) has elected Dr. Yong Chen, the Chief Technology Officer of Beckman Coulter Life Sciences, a Danaher company, to its College of Fellows. This is in recognition of his work in the field of medical and engineering innovation and discovery.
This honor follows in the footsteps of the founding fathers of the company, Dr. Arnold Beckman and Wallace Coulter, both previous fellows of this prestigious organization.
“In honoring Dr. Chen, the AIMBE recognizes the impact the CytoFLEX flow cytometer’s outstanding technology has had on the life sciences research space,” explained Mario Koksch, Vice President and General Manager of the Flow Cytometry Business Unit, Beckman Coulter Life Sciences.
“With its use of disruptive technologies, the CytoFLEX sets new standards of fluorescence sensitivity, enabling scientists to expand into new research areas using side scatter off the violet laser for enhanced nanoparticle detection.”
In 2012, Dr. Chen founded Xitogen Technologies Inc., a China-based startup to develop a revolutionary life science instrument. Xitogen was acquired by Danaher two years later; and Dr. Chen has spearheaded the production of the first new instrument to be launched since the acquisition, the Beckman Coulter CytoFLEX Flow Cytometer.
“I am honored to be recognized by the AIMBE and to join such an illustrious group of fellows,” Dr. Chen explained. “The considerable research facilities offered by Beckman Coulter Life Sciences, not just in the field of flow cytometry, creates a stimulating and innovative environment in which to explore the frontier of medical and biological engineering.”
